ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO454

A Randomized Controlled Trial of the Effects of Febuxostat Treatment on Markers of Endothelial Dysfunction and Renal Progression in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Ninwisut, Nanthawut, Phramongkutklao hospital, Bangkok, Thailand
  • Nata, Naowanit, Phramongkutklao hospital, Bangkok, Thailand
  • Thimachai, Paramat, Phramongkutklao hospital, Bangkok, Thailand
  • Varothai, Narittaya, Phramongkutklao hospital, Bangkok, Thailand
  • Tangwonglert, Theerasak, Phramongkutklao hospital, Bangkok, Thailand
  • Tasanavipas, Pamila, Phramongkutklao hospital, Bangkok, Thailand
  • Chaiprasert, Amnart, Phramongkutklao hospital, Bangkok, Thailand
  • Supasyndh, Ouppatham, Phramongkutklao hospital, Bangkok, Thailand
  • Satirapoj, Bancha, Phramongkutklao hospital, Bangkok, Thailand

Hyperuricemia relates to chronic kidney disease (CKD) progression, systemic inflammation and impaired endothelial function. Febuxostat, a novel nonpurine selective xanthine oxidase inhibitor, is potent and effective for decreasing serum uric acid levels. The study aimed to evaluate the effect of oral febuxostat on markers of endothelial dysfunction and renal function in CKD patients.


A total of 84 CKD stage III-IV patients with asymptomatic hyperuricemia were randomly assigned to either the febuxostat (40 mg/day, N=40) or the matching control (N=44) for 8 weeks. Serum uric acid, estimated glomerular filtration rate (eGFR), urine albumin, serum asymmetric dimethylarginine (ADMA), and high sensitivity C-reactive protein (hsCRP) were measured at baseline and at the end of study.


Febuxostat administration significantly reduced the serum uric acid concentration in patients with CKD when compared with control [ -3.40 (95% CI -4.19 to -2.62) vs. -0.35 (95% CI -0.76 to 0.06) mg/dL; P<0.001, respectively]. No significant difference in the changes in serum ADMA, hsCRP, eGFR and albuminuria, was identified between the two groups. Subgroup analysis in patients with decline serum uric acid after treatment, mean eGFR showed a significant increase in the febuxostat group (P=0.022), but no significant change in the palcebo group (P=0.802). The difference GFR change between groups was 1.97 ml/min/1.73 m2 with 95%CI 0.15 to 4.64 at 8 weeks (P=0.03). Adverse events specific to febuxostat were not observed.


Febuxostat effectively reduced serum uric acid in the population of CKD without effect to endothelial dysfunction and systemic inflammation. It was able to preserve renal function in subgroup CKD patients with lower serum uric acid level after treatment.